Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
《生物技術日報》:對阿卡迪亞的抗精神病藥物不屑一顧,Akebia 未通過 COVID-19 研究,這是卡齊亞令人鼓舞的腦轉移數據
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
FDA Signs Off Marker Therapeutics Cell Therapy Study In Lymphoma Setting
The FDA cleared Marker Therapeutics Inc's (NASDAQ:MRKR) Investigational New Drug (IND) application for MT-601 for relapsed/refractory non-Hodgkin lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment.
MT-601 is a multi-tumor-associated antigen (multiTAA)-specific T cell product targeting six antigens.
In addition, the FDA has cleared Marker to initiate its study at a dose level of 200 million cells per infusion versus...
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是過去24小時生物技術領域的熱門發展綜述:
Stocks In Focus
關注的股票
FDA Signs Off Marker Therapeutics Cell Therapy Study In Lymphoma Setting
FDA批准MARKER治療淋巴瘤的細胞治療研究
The FDA cleared Marker Therapeutics Inc's (NASDAQ:MRKR) Investigational New Drug (IND) application for MT-601 for relapsed/refractory non-Hodgkin lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment.
美國食品和藥物管理局批准了這一點。標記物治療公司中國(納斯達克代碼:MRKR)MT-601的研究新藥(IND)申請,用於治療未能或沒有資格接受抗CD19CAR T細胞治療的復發性/難治性非霍奇金淋巴瘤。
MT-601 is a multi-tumor-associated antigen (multiTAA)-specific T cell product targeting six antigens.
MT-601是一種針對六種抗原的多腫瘤相關抗原(MultiTAA)特異性T細胞產物。
In addition, the FDA has cleared Marker to initiate its study at a dose level of 200 million cells per infusion versus...
此外,FDA已經批准Marker啟動其研究...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧
點擊這裡與好友分享
暫無評論,快來留言吧!